Format

Send to

Choose Destination
Exp Ther Med. 2013 Oct;6(4):953-956. Epub 2013 Aug 5.

Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery.

Author information

1
Departments of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450012, P.R. China.

Abstract

The aim of this study was to investigate the effects of cytokine-induced killer (CIK) cell treatment combined with FOLFOX4 on the recurrence and survival rates of patients suffering from gastric cancer following surgery. A total of 98 patients with gastric cancer, who were surgically treated from June 2010 to June 2012, were divided into two groups: 47 patients, who underwent FOLFOX4 treatment alone, served as the control group, while the remaining 51 patients received FOLFOX4 in combination with CIK cell immunotherapy and served as the observation group. The immune functions, recurrence and survival rates were estimated and compared between the two groups. No significant differences were observed between the immune functions of the patients prior to treatment compared with the functions following treatment (P>0.05). However, the immune functions of the patients were improved following FOLFOX4 treatment in combination with CIK cell immunotherapy compared with the functions of the patients who received FOLFOX4 treatment alone (P<0.05). The gastric cancer recurrence rates of the patients in the observation group were significantly lower compared with those of the patients in the control group (5.9 versus 25.5, 17.6 versus 36.2 and 23.5 versus 48.9% after 1, 2 and 3 years, respectively; P<0.05). In addition, the survival rates of the patients with gastric cancer in the observation group were significantly enhanced compared with those of the control group, as assessed by log-rank test analysis (98.0 versus 93.6, 92.2 versus 78.7 and 72.5 versus 59.6% after 1, 2 and 3 years, respectively; P<0.05). It may be concluded that FOLFOX4 combined with CIK cell treatment has significant benefits for patients suffering from gastric cancer, compared with FOLFOX4 treatment alone.

KEYWORDS:

CIK cells; FOLFOX4; gastric cancer; recurrence rate; survival rate

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center